Maternal Plasma Soluble TRAIL is Decreased in Preeclampsia

Overview

Journal J Matern Fetal Neonatal Med

Publisher Informa Healthcare

Specialty Gynecology & Obstetrics

Date 2013 May 22

PMID 23688319

Citations 6

Authors

Piya Chaemsaithong

Tinnakorn Chaiworapongsa

Roberto Romero

Steven J Korzeniewski

Tamara Stampalija

Nandor Gabor Than

Zhong Dong

Jezid Miranda

Lami Yeo

Sonia S Hassan

Affiliations

Soon will be listed here.

Abstract

Objective: Preeclampsia (PE) is characterized by systemic intravascular inflammation. Women who develop PE are at an increased risk for cardiovascular disease in later life. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) has anti-atherosclerotic effects in endothelial cells and can mediate neutrophil apoptosis. Low soluble TRAIL (sTRAIL) and high C-reactive protein (CRP) concentrations are associated with an increased risk of future cardiovascular disease in non-pregnant individuals. The aim of this study was to determine whether maternal plasma concentrations of sTRAIL and CRP differ between women with PE and those with uncomplicated pregnancies.

Method: This cross-sectional study included women with an uncomplicated pregnancy (n = 93) and those with PE (n = 52). Maternal plasma concentrations of sTRAIL and CRP concentrations were determined by ELISA.

Results: 1) The median plasma sTRAIL concentration (pg/mL) was significantly lower and the median plasma CRP concentration was significantly higher in women with PE than in those with an uncomplicated pregnancy (25.55 versus 29.17; p = 0.03 and 8.0 versus 4.1; p = 0.001, respectively); 2) the median plasma concentration sTRAIL/CRP ratio was two-fold lower in women with PE than in those with an uncomplicated pregnancy (p < 0.001); and 3) women with plasma sTRAIL and CRP ratio in the lowest quartile were 8 times more likely to have PE than women with concentrations in the upper three quartiles (OR 8.9; 95% CI: 2.8-27.8).

Conclusion: Maternal plasma sTRAIL concentrations are lower (while those of CRP are higher) in women with PE than in those with uncomplicated pregnancies. These findings are consistent with the evidence of intravascular inflammation in this disorder.

Citing Articles

Proteomic profile of extracellular vesicles in maternal plasma of women with fetal death.

Gallo D, Fitzgerald W, Romero R, Gomez-Lopez N, Gudicha D, Than N J Matern Fetal Neonatal Med. 2023; 36(1):2177529.

PMID: 36813269 PMC: 10395052. DOI: 10.1080/14767058.2023.2177529.

Disruption in the Regulation of Immune Responses in the Placental Subtype of Preeclampsia.

Geldenhuys J, Rossouw T, Lombaard H, Ehlers M, Kock M Front Immunol. 2018; 9:1659.

PMID: 30079067 PMC: 6062603. DOI: 10.3389/fimmu.2018.01659.

The profiles of soluble adhesion molecules in the "great obstetrical syndromes".

Docheva N, Romero R, Chaemsaithong P, Tarca A, Bhatti G, Pacora P J Matern Fetal Neonatal Med. 2018; 32(13):2113-2136.

PMID: 29320948 PMC: 6070437. DOI: 10.1080/14767058.2018.1427058.

Feasibility of placenta-derived mesenchymal stem cells as a tool for studying pregnancy-related disorders.

Fuchi N, Miura K, Doi H, Li T, Masuzaki H Sci Rep. 2017; 7:46220.

PMID: 28401946 PMC: 5388876. DOI: 10.1038/srep46220.

TRAIL Is Decreased Before 20 Weeks Gestation in Women with Hypertensive Disorders of Pregnancy.

Zhou C, Long Y, Yang H, Zhu C, Ma Q, Zhang Y PLoS One. 2015; 10(6):e0128425.

PMID: 26030414 PMC: 4451764. DOI: 10.1371/journal.pone.0128425.

References

Seeds J . Impaired fetal growth: definition and clinical diagnosis. Obstet Gynecol. 1984; 64(3):303-10. View

Page N, Woods R, Gardiner S, Lomthaisong K, Gladwell R, Butlin D . Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia. Nature. 2000; 405(6788):797-800. DOI: 10.1038/35015579. View

Brosens I, Dixon H, Robertson W . Fetal growth retardation and the arteries of the placental bed. Br J Obstet Gynaecol. 1977; 84(9):656-63. DOI: 10.1111/j.1471-0528.1977.tb12676.x. View

Behboudi Gandevani S, Banaem L, Mohamadi B, Moghadam N, Asghari M . Association of high-sensitivity C-reactive protein serum levels in early pregnancy with the severity of preeclampsia and fetal birth weight. J Perinat Med. 2012; 40(6):601-5. DOI: 10.1515/jpm-2011-0190. View

Romero R . Prenatal medicine: the child is the father of the man. 1996. J Matern Fetal Neonatal Med. 2009; 22(8):636-9. DOI: 10.1080/14767050902784171. View

de Jonge L, Steegers E, Ernst G, Lindemans J, Russcher H, Hofman A . C-reactive protein levels, blood pressure and the risks of gestational hypertensive complications: the Generation R Study. J Hypertens. 2011; 29(12):2413-21. DOI: 10.1097/HJH.0b013e32834c58e5. View

Roberts J, Gammill H . Preeclampsia: recent insights. Hypertension. 2005; 46(6):1243-9. DOI: 10.1161/01.HYP.0000188408.49896.c5. View

Petrozella L, Mahendroo M, Timmons B, Roberts S, McIntire D, Alexander J . Endothelial microparticles and the antiangiogenic state in preeclampsia and the postpartum period. Am J Obstet Gynecol. 2012; 207(2):140.e20-6. PMC: 3432453. DOI: 10.1016/j.ajog.2012.06.011. View

Roberts J, Taylor R, GOLDFIEN A . Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens. 1991; 4(8):700-8. DOI: 10.1093/ajh/4.8.700. View

10.

Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic J, Yeo L . Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med. 2011; 39(6):641-52. PMC: 3213694. DOI: 10.1515/jpm.2011.098. View

11.

Redman C, Sargent I . Preeclampsia and the systemic inflammatory response. Semin Nephrol. 2004; 24(6):565-70. DOI: 10.1016/s0270-9295(04)00127-5. View

12.

Jacquemyn Y, Jochems L, Duiker E, Bosmans J, Van Hoof V, Van Campenhout C . Long-term renal function after HELLP syndrome. Gynecol Obstet Invest. 2004; 57(2):117-20. DOI: 10.1159/000075942. View

13.

Reuvekamp A, Poulina I, Capello J, Duits A . Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol. 1999; 106(10):1019-22. DOI: 10.1111/j.1471-0528.1999.tb08107.x. View

14.

Bouillet P, Strasser A . BH3-only proteins - evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. J Cell Sci. 2002; 115(Pt 8):1567-74. DOI: 10.1242/jcs.115.8.1567. View

15.

Schneider P, Bodmer J, Thome M, Hofmann K, Holler N, Tschopp J . Characterization of two receptors for TRAIL. FEBS Lett. 1997; 416(3):329-34. DOI: 10.1016/s0014-5793(97)01231-3. View

16.

Lykke J, Langhoff-Roos J, Sibai B, Funai E, Triche E, Paidas M . Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009; 53(6):944-51. DOI: 10.1161/HYPERTENSIONAHA.109.130765. View

17.

Rietzschel E, De Buyzere M . High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease?. Biomark Med. 2012; 6(1):19-34. DOI: 10.2217/bmm.11.108. View

18.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

19.

Brosens J, Pijnenborg R, Brosens I . The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecol. 2002; 187(5):1416-23. DOI: 10.1067/mob.2002.127305. View

20.

Levine R, Maynard S, Qian C, Lim K, England L, Yu K . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7):672-83. DOI: 10.1056/NEJMoa031884. View